Home   About this service   Get the news  
+32 2 743 34 03

 
UCB [BE0003739530 / UCB]

UCB Media Room: Disposal of own shares

INFORMATION REGLEMENTEE


[18/03/2020 | 20:00]
https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513=
9PTmAm2ORJ-2Fb7C-2B6emqiaYBkii-2BPfRBL8LeoOwV3haqn1ALKs4vU5VCZ3aMNDdC7v1Pp6=
MtM4G2NCtzQRcptkKAa6Ldi0RU14wpORt8QYdA_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7=
KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1=
waDGsf1ClzFRk3cnesDwnpYhyaGerozuhsJsJHXNebm3AgHxBK8F7d3e1u-2FCvhSIhh7dwmS4T=
pc7IeePrKoAxRusI5XUF7551L8fXlaYdOgS5uzku65XPY5b-2FBWcucr29dDNxP-2FpuOIBfAr6=
bKx67x2pX8UrmTybwkt6RbQmPsRXL2Fjo-2F6aGR2oo7HYhOBAjtH9KugC2IjAF4EFxBtF97v5Y=
bICrHifdju4IKz-2FizLHcvbpp7Zd0JYTlKUTFkJPzI-3D

** Disposal of own shares
------------------------------------------------------------

Brussels (Belgium), 18 March 2020 =E2=80=93 20:00 (CET) =E2=80=93 regulated=
information

In application of article 8:6 of the Royal Decree executing the new Belgian=
Code of Companies and Associations, UCB SA/NV announces that following exe=
rcises of stock options by its employees, it has disposed of UCB shares OTC=
in view of deliveries of shares to the relevant employees, within the fram=
ework of the Long Term Incentive Program of the UCB Group, as follows:

https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513=
9PTmAm2ORJ-2Fb7C-2B6emqiaYBkii-2BPfRBL8LeoOwVJp-2BLHfheT-2B3z3WAyC4Ri-2FP2C=
stvhZtZZexQInL89NQA3AUsZx-2BvmeaX5lFHCjjQK_a2H_xDPID0vOuylFAU8fv4e60wei4Jxq=
EGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2=
F2X9c9g1waDGsf1ClzFRk3cnesDwnpYhyaGerozuhsJsJHXNebm3AgHxBK8F7d3e1u-2FCvhSIh=
h7dwmS4Tpc7IeePrKoAxRusI5XUF7551L8fXlaYdOgS0naIzP4cyeGQiFAZR0Gs0nYVY5fty1ky=
viBVP47wY3D8za5GeUXnT90rVcIAxu0xscdWAg9-2F6Tch3A5FXIVD3oR7SIK5wlpS-2BMW7O5t=
S85rahXYMgQ-2FCnpCmgBNrIZfH4fqy-2BLg94TyKbpBkgem7z8-3D
=C2=A0
This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQ=
yQ53jATUXZJD59ZUodhGC-2FyJVE-2BjXw-2Fd0j1C70r-2FZ058zOLCiGbx-2FzvKhSzxYKNx1=
8dK5MiuQ-3D-3DmPTx_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bS=
l0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1waDGsf1ClzFRk3cnesDw=
npYhyaGerozuhsJsJHXNebm3AgHxBK8F7d3e1u-2FCvhSIhh7dwmS4Tpc7IeePrKoAxRusI5XUF=
7551L8fXlaYdOgS2dog8FzBZXUT9aNueKxqhPQMCHulMA6J-2FuXOjMdsAKKYdn1sMKya4yj4sR=
qfhKFD57D8Gxk4yUpOx-2FD6H0ot6gPxDc6iKCHG-2BR-2FuOtnsSMBXPKmfH6J4ZYOHHgQ-2Bs=
0V5IutItjTKiqcpyxtqxJQGIo-3D .

Investor Relations
Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
=C2=A0Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0

=C2=A0=C2=A0 =C2=A0

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With 7 500 people in approxima=
tely 40 countries, the company generated revenue of =E2=82=AC 4.9 billion i=
n 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twit=
ter: @UCB_news
=C2=A0
Image
Chart 1 Disposal of Own Shares March 18 2020 (https://u7061146.ct.sendgrid.=
net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6emqiaYBki=
i-2BPfRBL8LeoOwVJp-2BLHfheT-2B3z3WAyC4Ri-2FJBBK-2FPpWENKkAj0Dob9Fi0-3DJmbJ_=
xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2F=
BZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1waDGsf1ClzFRk3cnesDwnpYhyaGerozuhsJsJHX=
Nebm3AgHxBK8F7d3e1u-2FCvhSIhh7dwmS4Tpc7IeePrKoAxRusI5XUF7551L8fXlaYdOgS3azE=
59LvdK6AfgNd7KSTeBcTZyAxHtX2zc47jKS8QVJDTAWQkoK1oeSoUIGO1ynIQ5Wj-2FT4I1-2FI=
UJHs2JrtQvyXwXhFAhrabRsL-2FxEJJaZ-2FOkxO8Ssp8YRIPnQtezO4GyNigpAsP3SxPT5IvrN=
kF5k-3D GenericFile
200318- Disposal of own shares (https://u7061146.ct.sendgrid.net/ls/click?u=
pn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6emqiaYBkii-2BPfRBL8LeoO=
wVtKqgB4KJ-2B-2FDY1QP6lq5YfiCVEJUT-2ByJZlazKpTN5-2BEY-3D1eJz_xDPID0vOuylFAU=
8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FO=
eoCOG9ekocVj-2F2X9c9g1waDGsf1ClzFRk3cnesDwnpYhyaGerozuhsJsJHXNebm3AgHxBK8F7=
d3e1u-2FCvhSIhh7dwmS4Tpc7IeePrKoAxRusI5XUF7551L8fXlaYdOgS-2FNg-2FoMV1kELjrG=
wj3X60cue7juZJXqAO-2BN6xaOqz5lyYGKYGd4Ijug6oaqXh597-2BF2jaKvY8dGPpKVFhk6CCr=
FlzrVPiEsC3B95gE2H2-2FxGKl3t-2BPc8OWsaJdNOiFUKdad4IwZYBS77-2BzJXt1F2kkA-3D =
GenericFile
200318 - Ali=C3=A9nation d actions propres (https://u7061146.ct.sendgrid.ne=
t/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6emqiaYBkii-=
2BPfRBL8LeoOwV39qniyj70PRiryogpKdvgK-2Bw71UF7uRsmiZlkz1UIT0-3D5O50_xDPID0vO=
uylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Z=
lf-2FOeoCOG9ekocVj-2F2X9c9g1waDGsf1ClzFRk3cnesDwnpYhyaGerozuhsJsJHXNebm3AgH=
xBK8F7d3e1u-2FCvhSIhh7dwmS4Tpc7IeePrKoAxRusI5XUF7551L8fXlaYdOgSxyKm18peFIeC=
SFEud27P1w27lgUAMh61pXroVIB451te7QyA-2F2K1eMlWN7oLHDwVgPUma22AU9m1m1K8fef5c=
LEyi79str5Bsik1rx6JtYlG9muC8oBMNXjhlPd3G1ZgEVuOKvp6a-2BcE9ZarwCDIjs-3D Gene=
ricFile
200318- Vervreemding van eigen aandelen (https://u7061146.ct.sendgrid.net/l=
s/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6emqiaYBkii-2BP=
fRBL8LeoOwVZcjdTmSoq2QpQOo0YvcFy6DT-2F7iYJ21VTPRSjKYwEaQ-3Duobd_xDPID0vOuyl=
FAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-=
2FOeoCOG9ekocVj-2F2X9c9g1waDGsf1ClzFRk3cnesDwnpYhyaGerozuhsJsJHXNebm3AgHxBK=
8F7d3e1u-2FCvhSIhh7dwmS4Tpc7IeePrKoAxRusI5XUF7551L8fXlaYdOgS0x8ZXTH15wAscdt=
O1JYF9QK8RHlU4gxCswTdkmcMphugoV3IOXAZHlimv2MBqms8QlqfLuTS-2BwYACtb4zj2DVOPW=
sZuadV3C-2BM1piXCvwPfKxcXyD6dzZzRECl0Z1Kmg1ppNLEXnLC1kRkSRBXs5Go-3D=0D
=0D
______________________=0D
If you would rather not receive future communications from UCB SA, please g=
o to https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jAT=
UeYfdhr1xEBQnaPhR2RKx1tfe2VKDZTewv5u80JomRcX-2BQJTkFXqVbYGYfvFyo475wJ6I-2BS=
P0HP5HL5JyxjnXh9SmyMhXDr17MwLXfbeeUfKly2T9HC7PwQ8lFr6qWuftJ6pVDu1J5arad7KlI=
lKAEE-3Djvnh_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvP=
s6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1waDGsf1ClzFRk3cnesDwnpYhya=
GerozuhsJsJHXNebm3AgHxBK8F7d3e1u-2FCvhSIhh7dwmS4Tpc7IeePrKoAxRusI5XUF7551L8=
fXlaYdOgS6pmR-2Fjt-2FXDSXju7f-2B3-2BdbHzkW-2BocBrT844o-2BDg9hbjCVKsoPY4YfQB=
bwXD1cx7f9gM81ggnCCfm6FTEZenKF2DmHrSOdGs0aZSIgl4Mqxej2eAimixQ5ZIiogFXcZbqOu=
JKLDuQyP6zm2dwSd5m2Lc-3D=0D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=